DPCP

SNC-Lavalin announces having reached a remediation agreement with the Quebec Crown Prosecutor's Office concerning charges laid in September 2021 in connection with the Jacques Cartier Bridge project for events that occurred between 1997 and 2004

Retrieved on: 
Friday, May 6, 2022
Negotiation, DPCP, Twitter, Maintenance, SNC, Company, Engineering, SNC-Lavalin, Agreement, In re Caremark International Inc. Derivative Litigation, Quebec Superior Court, Operation, LinkedIn, National Engineering Services Pakistan, Intention, Confidentiality, TSX, BBC Design & Engineering, Operational maintenance, Solution, Technology, News, Risk management

The financial components of the remediation agreement provide for payments totalling $29,558,777 over a period of 3 years.

Key Points: 
  • The financial components of the remediation agreement provide for payments totalling $29,558,777 over a period of 3 years.
  • The remediation agreement is subject to approval by the Quebec Superior Court, which will be sought at a hearing scheduled to begin on May 10, 2022.
  • Contemporaneously with laying the charges, on September 23, 2021, the DPCP had invited SNC-Lavalin Inc. and SNC-Lavalin International Inc. to negotiate a remediation agreement regarding said charges.
  • As the Company is bound by confidentiality restrictions, it cannot comment further on this matter until judicial procedures are completed.

SNC-Lavalin acknowledges the charges relating to alleged events that took place nearly two decades ago and welcomes the Directeur des poursuites criminelles et pénales' (DPCP) invitation to negotiate a remediation agreement

Retrieved on: 
Thursday, September 23, 2021
People, Criminal code, Operational maintenance, Ethisphere Institute, Organisation for Economic Co-operation and Development controversy, World Bank, U.S, TSX, Economy, News, Culture, Engineering, DPCP, SNC, United Nations Global Compact, National Building Code of Canada, World, SNC-Lavalin, Development, World Bank Group, Compliance, Organization, Twitter, CEO, Company, Risk, Fraud, Design & Engineering Methodology for Organizations, Technology, Transparency International, Capital, U.S. Department of Defense Strategy for Operating in Cyberspace, Maintenance, Government, Pharmaceutical industry

The Company welcomes theopportunity offered by the DPCP to negotiate a remediation agreement to resolve these charges.

Key Points: 
  • The Company welcomes theopportunity offered by the DPCP to negotiate a remediation agreement to resolve these charges.
  • This is first time a Canadian company has received an invitation to negotiate such an agreement.
  • The Company, which is today recognized for its robust integrity program and culture, takes seriously these charges relating to alleged events that took place two decades ago.
  • The investigation of this matter has been disclosed in the Company's public filings and was facilitated by its own self-reporting.

RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

Retrieved on: 
Friday, May 18, 2018
RTT, Cancer, Medicine, Microbiology, Wart, Plantar wart, Human papillomavirus infection, Diphenylcyclopropenone, Papillomaviridae, DPCP, Papilloma

This study evaluated the safety and effectiveness of Samcyprone, a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP), for the treatment of common warts.

Key Points: 
  • This study evaluated the safety and effectiveness of Samcyprone, a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP), for the treatment of common warts.
  • Complete wart clearance throughout the study was 54.0% for all warts, and up to 71.4% for certain wart types (non-plantar warts).
  • Sc., RXi's Chief Development Officer commented: "We are very pleased with these results, as they are a significant improvement over currently used treatment options.
  • Samcyprone is being studied for the treatment of cutaneous warts, which are benign epidermal tumors caused by human papillomaviruses (HPVs).